3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Renal Cell
9
Prostatic Neoplasms
8
Urinary Bladder Neoplasms
7
Melanoma
7
Neoplasms
5
Head and Neck Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Carcinoma, Merkel Cell
3
Squamous Cell Carcinoma of Head and Neck
2
Kidney Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Uterine Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Penile Neoplasms
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Interventions
pembrolizumab
1
enzalutamide
1
cemiplimab
1
abiraterone
1
Stents
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Immune Checkpoint Inhibitors
1
Etanercept
1
Cytochrome P-450 Enzyme System
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bites and Stings
×
cemiplimab
×
Genitourinary
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled